Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 179Urinary Bladder Neoplasms 31Carcinoma, Renal Cell 19Kidney Neoplasms 18Breast Neoplasms 13Wilms Tumor 11Neoplasms 10Neoplasm Metastasis 10Lung Neoplasms 9Testicular Neoplasms 8Testicular Germ Cell Tumor 6Melanoma 6Carcinoma, Non-Small-Cell Lung 6Non-Muscle Invasive Bladder Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Endometrial Neoplasms 5Dendritic Cell Sarcoma, Interdigitating 5Burkitt Lymphoma 5Vaginal Neoplasms 4Uterine Cervical Neoplasms 4Urethral Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Seminoma 4Sarcoma 4Recurrence 4Rectal Neoplasms 4Radiation Injuries 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4

Interventions

abiraterone 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligometastatic Prostate Carcinoma × Radiotherapy × Genitourinary × Clear all
NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Mayo Clinic

Phase 2 Recruiting
110 enrolled
Genitourinary

Oligometastatic Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡